

## [Glp5,(Me)Phe8,Sar9] Substance P (5-11)

Cat. No.:	HY-P3801
CAS No.:	77128-69-9
Molecular Formula:	C <sub>43</sub> H <sub>61</sub> N <sub>9</sub> O <sub>9</sub> S
Molecular Weight:	880.06
Sequence:	pGlu-Gln-Phe-N-Methyl-Phe-Sar-Leu-Met-NH2
Sequence Shortening:	pGlp-QF(-Me)F-Sar-LM-NH2
Target:	Neurokinin Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

Description	<p>[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is a <a href="#">Substance P</a> (HY-P0201) analogue that has approximately the same effects as <a href="#">Substance P</a> (HY-P0201) on neurokinin 1 receptor (NK1R) in rat brain, but with a much longer duration of action. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) selectively activates dopamine metabolism in the mesencephalon and midbrain cortex of the rat brain. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) also increases motor activity and induces recovery of addictive agent-seeking behavior in rats<sup>[1][2][3]</sup>.</p>																
In Vivo	<p>[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (2 µg/side; inject into the ventral tegmental area; single) exhibits selective activation of mesolimbic and mesocortical dopamine metabolism in rat brain<sup>[1]</sup>.</p> <p>[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (0.5, 1.5, 3 µg/side; inject into the ventral tegmental area; single) increases motor activity and induces recovery of addictive agent-seeking behavior in rats<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Male Sprague-Dawley rats (300-350 g)<sup>[1]</sup>.</td> </tr> <tr> <td>Dosage:</td> <td>2 µg/side</td> </tr> <tr> <td>Administration:</td> <td>Inject into the ventral tegmental area; single</td> </tr> <tr> <td>Result:</td> <td>Selectively activated mesolimbic and mesocortical dopamine metabolism.</td> </tr> </table> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Male Wistar rats (300-350 g)<sup>[2]</sup>.</td> </tr> <tr> <td>Dosage:</td> <td>0.5, 1.5, 3 µg/side</td> </tr> <tr> <td>Administration:</td> <td>Inject into the ventral tegmental area; single</td> </tr> <tr> <td>Result:</td> <td>Significantly increased locomotor activity when at 3 µg/side.</td> </tr> </table>	Animal Model:	Male Sprague-Dawley rats (300-350 g) <sup>[1]</sup> .	Dosage:	2 µg/side	Administration:	Inject into the ventral tegmental area; single	Result:	Selectively activated mesolimbic and mesocortical dopamine metabolism.	Animal Model:	Male Wistar rats (300-350 g) <sup>[2]</sup> .	Dosage:	0.5, 1.5, 3 µg/side	Administration:	Inject into the ventral tegmental area; single	Result:	Significantly increased locomotor activity when at 3 µg/side.
Animal Model:	Male Sprague-Dawley rats (300-350 g) <sup>[1]</sup> .																
Dosage:	2 µg/side																
Administration:	Inject into the ventral tegmental area; single																
Result:	Selectively activated mesolimbic and mesocortical dopamine metabolism.																
Animal Model:	Male Wistar rats (300-350 g) <sup>[2]</sup> .																
Dosage:	0.5, 1.5, 3 µg/side																
Administration:	Inject into the ventral tegmental area; single																
Result:	Significantly increased locomotor activity when at 3 µg/side.																

### REFERENCES

- 
- [1]. Elliott PJ, et al. Selective activation of mesolimbic and mesocortical dopamine metabolism in rat brain by infusion of a stable substance P analogue into the ventral tegmental area. *Brain Res.* 1986 Jan 15;363(1):145-7.
- [2]. Eison AS, et al. Substance P analog, DiMe-C7: evidence for stability in rat brain and prolonged central actions. *Science.* 1982 Jan 8;215(4529):188-90.
- [3]. Placenza FM, et al. Infusion of the substance P analogue, DiMe-C7, into the ventral tegmental area induces reinstatement of cocaine-seeking behaviour in rats. *Psychopharmacology (Berl).* 2004 Dec;177(1-2):111-20.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA